Scilex Holding (SCLXW) Change in Inventory (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Change in Inventory of -$257000.0 in Q1 2026, up 49.51% quarter-over-quarter from -$509000.0 in Q4 2025, and down 144.01% on a YoY basis from $584000.0 in Q1 2025.
Scilex Holding (SCLXW) Change in Inventory (2022 - 2026) Analysis & Trends
Scilex Holding's Change in Inventory history runs 5 years deep, the most recent figure standing at -$257000.0 for Q1 2026.
- In Q1 2026, Change in Inventory fell 144.01% year-over-year to -$257000.0; the TTM figure through Mar 2026 stood at -$2.6 million (down 1636.84% YoY), while the FY2025 annual figure was -$1.8 million, down 23.05% from the prior year.
- Change in Inventory was -$257000.0 for Q1 2026 at Scilex Holding, up from -$509000.0 in the prior quarter.
- In the past five years, Change in Inventory ranged from a high of $897000.0 in Q1 2023 to a low of -$1.4 million in Q3 2025.
- Historically, Change in Inventory has averaged -$109647.1 across 5 years, with a median of -$257000.0 in 2026.
- The sharpest annual moves came in 2023 and 2025: Change in Inventory soared 466.96% in 2023, then plunged 1597.06% in 2025.
- A 5-year view of Change in Inventory shows it stood at $445000.0 in 2022, then plunged by 38.65% to $273000.0 in 2023, then slumped by 87.55% to $34000.0 in 2024, then slumped by 1597.06% to -$509000.0 in 2025, then soared by 49.51% to -$257000.0 in 2026.
- The last three Change in Inventory figures came in at -$257000.0 (Q1 2026), -$509000.0 (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 431.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 184.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -18.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 52.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -14.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -257,000.00 |
| Mar 31, 2026 | -257,000.00 |
| Dec 31, 2025 | -509,000.00 |
| Dec 31, 2025 | -509,000.00 |
| Sep 30, 2025 | -1.38 Mn |
| Sep 30, 2025 | -1.38 Mn |
| Jun 30, 2025 | -496,000.00 |
| Jun 30, 2025 | -496,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | -358,000.00 |
| Sep 30, 2024 | -358,000.00 |
| Jun 30, 2024 | -412,000.00 |
| Jun 30, 2024 | -412,000.00 |
| Mar 31, 2024 | -726,000.00 |
| Mar 31, 2024 | -726,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |